Hepatitis related to the Chinese medicine Shou-wu-pian manufactured from Polygonum multiflorum
But PP, Tomlinson B, Lee KL. Hepatitis related to the Chinese medicine Shou-wu-pian manufactured from Polygonum multiflorum. Vet Hum Toxicol. 1996;38:280-282.
Acute hepatitis due to Shen-Min, a herbal product derived from Polygonum multiflorum
Cárdenas A, Restrepo JC, Sierra F, et al. Acute hepatitis due to Shen-Min, a herbal product derived from Polygonum multiflorum. J Clin Gastroenterol. 2006;40:629-632.
New case of acute hepatitis following the consumption of Shou Wu Pian, a Chinese herbal product derived from Polygonum multiflorum [Letter]
Mazzanti G, Battinelli L, Daniele C, et al. New case of acute hepatitis following the consumption of Shou Wu Pian, a Chinese herbal product derived from Polygonum multiflorum [Letter]. Ann Intern Med. 2004;140:W30.
Recurrent toxic hepatitis in a Caucasian girl related to the use of Shou-Wu-Pian, a Chinese herbal preparation [Case Report]
Panis B, Wong DR, Hooymans PM, et al. Recurrent toxic hepatitis in a Caucasian girl related to the use of Shou-Wu-Pian, a Chinese herbal preparation [Case Report]. J Pediatr Gastroenterol Nutr. 2005;41: 256-258.
Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum [Case Report]
Park GJ, Mann SP, Ngu MC. Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum [Case Report]. J Gastroenterol Hepatol. 2001;16:115-117.
Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry Q3A Impurities in New Drug Substances (Internet). Baltimore (MD): International Conference on Harmonisation (ICH); c1996. Modified February, 2003. Available at: http://www.fda.gov/cber/ gdlns/ichq3a.htm. Accessed February 22, 2006.
Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry Q3A Impurities in New Drug Substances (Internet). Baltimore (MD): International Conference on Harmonisation (ICH); c1996. Modified February, 2003. Available at: http://www.fda.gov/cber/ gdlns/ichq3a.htm. Accessed February 22, 2006.
7
0041530157
High prevalence of potentially hepatotoxic supplement use in patients with fulminant hepatic failure
Estes JD, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic supplement use in patients with fulminant hepatic failure. Arch Surg. 2003;138: 852-858.